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There is intense contemporary interest in the identity, stability, and potential of stem cells, in the body or in the
lab. The unusually comprehensive view provided by the 7th annual meeting of the ISSCR provides a frame-
work to summarize recent progress.More than 3100 researchers traveled to Barcelona in July for the
2009 annual meeting of the International Society for Stem Cell
Research. To reflect the enthusiasm of this young and rapidly
growing scientific society, we use a style that is informal but
hopefully informative to summarize the main themes that were
discussed. The meeting started with a focus on the brain and
ended with pluripotency. Along the way, participants from 56
different countries (see Figure 1) discussed advances in many
areas of stem cell biology.
Brain Disease and Repair
The excitement in the stem cell field is derived from many sour-
ces, one of the most significant being relevance to human health
and disease. Advances in stem cell biology are often presented
as bringing us closer to therapies for neurodegenerative disease.
To provide a context for this goal, the opening session focused
on the development and regeneration of the brain. NancyWexler
(Columbia University, New York City) opened with a description
of how the presence of Huntington’s disease (HD) in her family
led her to the Lake Maracaibo region of Venezuela. Using videos
of patients and their families, Nancy showed how the disease
alters movement and how the effects are distinct in different
people. The large pedigree gathered around Lake Maracaibo
led to HD being the first genetic disease mapped using the tech-
niques of DNA chemistry. HD is one of several brain disorders
caused by an expansion of a polyglutamine region that is often
associated with abnormal protein aggregates or inclusions in
the nuclei of cells. Even though HD is highly penetrant, individ-
uals with the same number of repeats have very different
patterns of disease. Contemporary analysis of the Venezuela
kindred is focused on the identification of other genomic regions
that modify the severity of the disease. Elena Cattaneo (Univer-
sity of Milan) continued this theme. She described a series of
experiments that started with cellular models and culminated
in clinical studies showing mutant htt alters the expression of
a growth factor (BDNF) and the receptor TrkB that promote
neuronal survival (Zuccato et al., 2008). These changes in gene
expression are linked to activation of the REST/NRSF repressor
that regulates fundamental features of neural differentiation.
REST interacts physically and genetically with other members
of a protein complex that represses transcription. This complex
includes the methyl-CpG-binding protein 2 (MeCP2). Loss or
gain of MeCP2 expression causes a range of neurological andpsychiatric disability, Rett syndrome. Fred ‘Rusty’ Gage (Salk
Institute, La Jolla) discussed a novel function of MeCP2 in the
developing brain. Long interspersed nuclear elements-1 (Line-
1 or L1) are derived from retrotransposons and represent
>15% of the human genome. When they are transcribed, these
RNAs can retrotranspose into new genomic locations where
they cause somatic mosaicism that is associated with clinical
disease. L1 promoters have CpG islands, and their transcription
increases as neural precursors differentiate. It is now clear that
there are increased numbers of L1 insertions in the genome of
human brain cells, implying that loss of MeCP2 is mutagenic,
providing a potentially novel cause of disease (Coufal et al.,
2009). The interaction of multiple genetic loci is a confounding
issue for most diseases. In HD and Rett, stem cell biology is
providing new tools to understand how mutations lead to the
pathological mechanisms.
The mechanisms controlling stem cell differentiation in the
central and peripheral nervous systemwere presented by Yukiko
Gotoh (University of Tokyo) and Marianne Bronner-Fraser (Cal-
tech, Pasadena). Their presentations showed that our growing
ability to define specific steps in the neural lineage provides
fundamental rules controlling cell fate and survival in the brain.
The generation of dopamine neurons from stem cells has stimu-
lated a great deal of work on the ex vivo development of this cell
type, but recent work suggests that grafted dopamine neurons
acquire disease in Parkinson’s patients. Etienne Hirsch (Salpe-
triere Hospital, Paris) presented clear evidence that dopamine
neurons are killed by CD4+ T cells (Brochard et al., 2009). A
similar finding, a non-cell-autonomous cause of neuronal death,
has been obtained in models of amyotrophic lateral sclerosis
(ALS). In this case, motor neurons die when the initiating muta-
tion is expressed in either immune or vascular cells, but not in
cells of the brain (Yamanaka et al., 2008). Cell therapy is often
presented as the justification for the major effort to generate
human neurons from pluripotent cells. As these presentations
showed, neurodegeneration is caused by a pathology that
involves multiple cell types. Regenerative medicine will have to
develop an understanding of the cell interactions and widely
dispersed pathology that put patients at risk.
In the Endoderm
Allan Spradling (Carnegie Institute, Baltimore) showed that the
Drosophila hindgut has quiescent stem cells that can divide inCell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCR 483
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In mammals, the existence of intestinal stem cells has been
known since the work of LeBlond and colleagues in the 1960s.
However, until this year, there has been no rigorous demonstra-
tion of the clonal growth of intestinal stem cells in vitro. Han
Clevers (Hubrecht Institute, Utrecht) described work showing
that single cells from the adult intestinal crypt would proliferate
form structures that contain both a crypt and a villus, the two
morphological domains of many regions of the gut. These model
intestinal units would self-renew in vitro, clearly meeting the two
in vitro criteria for stem cells. This process occurs in the absence
of other niche cells, perhaps because Paneth cells at the crypt
base produce all the factors necessary (Sato et al., 2009).
The clonal expansion in vitro occurs when a specific cell type
expressing the LGR5 gene was isolated. LGR5 (leucine-rich-
repeat containing G protein-coupled receptor 5) was isolated
as a Wnt signaling target gene in the intestine. LGR5-positive
cells are normally seen in the base of the crypt and, as expected
for a stem cell, their marked progeny are found throughout intes-
tinal crypts and villi (Barker et al., 2007). Interestingly, Cappechi
and colleagues have reported a similar lineage-tracing strategy
to mark the progeny of cells expressing the polycomb gene
Bmi1. Bmi1+ and LGR5+ cells are normally distinct, but both
cell types give rise to entire crypts (Sangiorgi and Capecchi,
2008). The lineage-tracing data suggest that these two putative
intestinal stem cell types can give rise to one another. It is
clear that the precision of in vivo tracking and clonal in vitro
assays are prompting new assessment of the potential of intes-
tinal cells.
Figure 1. The 7th Annual Meeting in Barce-
lona Drew a Large and Diverse Audience
of Attendees
(A) FionaWatt opening themeeting. The difference
in scale between the video images and the distant
brightly lit figure of the President of our society
gives a visual sense of the size of the meeting
room and the scope of the program.
(B) The geographic origin of the participants at the
6th Annual Meeting in 2008 versus the 7th Annual
Meeting in 2009.
Along the whole length of the endo-
derm, outgrowths of the gut tube form
specialized organs. From the perspective
of human disease, the liver and pancreas
are among the most significant of these
endodermal structures. Claude Bernard
showed that the liver pumps sugar into
the blood. Through the production of
insulin, the pancreas takes sugar out of
the blood. Pancreatic dysfunction leads
to high levels of glucose in the blood,
and the frequency of diabetes is stimu-
lating many different approaches to
generate or control the insulin-producing
pancreatic b cells. There are two major
types of cells in the pancreas: the
exocrine cells secrete enzymes into the
gut, and the endocrine cells secrete insulin and other hormones
into the blood. At one time, these cell types were thought to be
developmentally distinct, but Sara Ferber (Sheba Medical
Center, Tel-Hashomer) suggested that exocrine or liver cells
can be transfated into endocrine cells. The insulin-producing
b cells themselves can divide in vivo, providing another target
for regulation (Dor et al., 2004). Harry Heimberg (Vrije University
Brussel, Brussels) used a pancreatic injury model (duct ligation)
to identify another precursor (NGN3+ ductal cells) that has the
ability to produce new b cells (Xu et al., 2008). Heimberg is
now looking to see if LGR5 marks this putative stem cell popula-
tion in the pancreas, following the suggestion that LGR5 marks
stem cell populations in many tissues.
The development of a cell therapy based on endocrine
pancreatic cells would require large amounts of tissue. The
reports that both mouse and human ESCs can generate pancre-
atic endocrine cells suggest that pluripotent cells may be a suit-
able source. To achieve the controlled production of differenti-
ated cell types from pluripotent human cells, the several steps
in this ex vivo development must be defined and optimized.
Doug Melton (Harvard University, Boston) described the identifi-
cation of a small molecule that boosts the production of an early
endodermal cell (Borowiak et al., 2009). Melton argued that it
was possible to develop robust technologies for each step of
the lineage from a pluripotent stem cell to a functional b cell.
The lung is an outgrowth of the endoderm at a more anterior
location. Mark Krasnow (Stanford University) also employed
drug-inducible lineage tracing to identify separate epithelium,
smoothmuscle, and endothelial clones during lung development484 Cell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCR
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subroutines of lung epithelial lineage control the branching
morphology that is characteristic of the lung (Metzger et al.,
2008). Stay tuned for further advances when this approach is
combined with a recent detailed identification of dividing cells
in the developing mouse lung (Rock et al., 2009). These experi-
ments make the lung one of the best-understood organs in the
developing mouse. Using a dramatic combination of stem cells
and tissue engineering, Paola Macchiarini (Hospital Clinico de
Barcelona) replaced the damaged primary bronchial airway
tube in a 30-year-old human. Macchiarini took a decellularized
tracheal tube and then seeded it with autologous respiratory
epithelial stem cells on the inside and autologous chondrocyte
precursor cells on the outside (Macchiarini et al., 2008). This bio-
engineered organ produced recovery of breathing in the patient.
In the Mesoderm
Hematopoietic stem cells are often considered the ‘‘gold stan-
dard’’ in terms of the quality and scope of the experiments that
validate the stem cell population at different stages of develop-
ment and adult life. Despite the apparent maturity of this field,
there are many open questions. One of these is the specification
and precise identity of hematopoietic stem cells at different
stages of development. Ana Cumano (Pasteur Institute, Paris)
investigated the origin of these cells by using c-kit as a marker
fordetailed tracingexperiments in thedevelopingmurineembryo.
She defined a unique combination of surface markers and tran-
scription factors in the region of the embryo where HSCs are first
found, the Aortic-Gonadal-Mesonephric (AGM) region. These
data define differences between embryonic hematopoietic stem
cells and their counterparts at later stages in development in
the fetal liver or the adult bone marrow (Bertrand et al., 2005).
Andreas Trumpp (DKFZ, Heidelberg) identified two HSC pop-
ulations: one that normally divides once every 30 days (‘‘active’’;
85% of HSCs), and another that divides perhaps five times over
the lifetime of the animal (‘‘dormant’’; 15%) (Wilson et al., 2008).
Only active HSCs make progenitors under baseline conditions,
and dormant HSCs are activated following stress (5-FU treat-
ment). Treatment with interferon alpha (IFNA1) can make
dormant HSCs go from G0 to G1, effectively activating them.
He suggested that ‘‘priming’’ with IFNA1 before starting chemo-
therapy might be a way of killing tumor cells and the dormant
cancer stem cells and reported that this has worked in six
patients with leukemia (Essers et al., 2009).
In normal hematopoiesis, HSCs generate multiple distinct cell
types. An important feature of this model is that cells are
committed to different branches of the blood lineage. Meinrad
Busslinger (Institute of Molecular Pathology, Vienna) discussed
the transcription factor Pax5, which emerges as a critical
‘‘gate-keeping’’ molecule, suppressing the lineage-inappro-
priate expression of genes during lymphocyte differentiation.
From their first discovery, the pattern of expression of Pax
transcription suggested a role in specifying cell type. Other
work, particularly on the role of Pax6 in specification of eye
development, confirms that Pax genes can define cell type.
Pax5 has a continuing role maintaining distinctions between
different branches of the lineage in the blood. Detailed analysis
of the transcriptional control of the Pax5 gene during develop-
ment shows that Polycomb action represses the gene until theearly B cell stage of development (Decker et al., 2009). B cells
can easily switch fates without Pax5. Further insight into the
stability of hematopoietic lineages will come from analysis of
the gate-keeping functions of Polycomb and Pax genes.
In the blood, there is good evidence for an early founder cell
that also generates vascular cells. This is also true for skeletal
muscle. Work from Margaret Buckingham (Pasteur Institute)
has shown that Pax3 and Pax7 specify two types of muscle
precursor. They have now demonstrated that a balance between
PAX3/7 and FOXC2 in somites was critical for the choice
between skeletal muscle and vascular fates in a mesodermal
stem cell. From bone marrow, an adherent cell can be isolated
that grows in cell culture and supports the survival of HSCs.
This cell has been extensively studied and is known to generate
bone, smooth muscle, and fat cells. A similar cell can be found in
other tissues, including skeletal muscle, and it seemed possible
that many tissues contain thesemesenchymal stem cells (MSCs)
in addition to the tissue-specific stem cell. Paolo Bianco (Univer-
sity of Rome) made a strong case that MSCs are restricted to the
bone marrow and that other tissues do not generate MSCs.
Further work in this area may define tissue-specific stem cells
at a new level of precision.
In most mammalian tissues, we know little about the mecha-
nisms that control the number of stem cells. Debbie Yelon (Skir-
ball Institute, New York) is analyzing the network of signals that
control the size of the cardiac progenitor pool in zebrafish.
By developing a chemical caging-based method to fate-map
cardiac progenitor cells, she showed that the number of cardiac
progenitor cells largely determines heart size (Keegan et al.,
2004). Other data shows that hedgehog is required to maintain
the cardiac progenitor pool and that retinoid signaling plays
a repressive role in regulating heart size (Keegan et al., 2005).
These inductive and repressive signals regulate the size of the
heart in development and place any future work on cardiac
stem cells in the context of the entire development of the organ,
a mega-niche.
The practical consequences of understanding stem and
progenitor cells in the blood were the subject of presentations
by Leonard Zon (Children’s Hospital Boston) and Claudio Bor-
dignon (Vita-Salute San Raffaele University, Milan). The blood
from the umbilical cord of newborn infants contains HSCs, but
there are too few to reconstitute the marrow of an adult. Using
the zebrafish system, Leonard Zon found that prostaglandins
enhance the ability of HSCs to engraft. Remarkably, these
results were confirmed in a mouse model, and a clinical trial is
underway only 2 years after the first discovery (Goessling
et al., 2009; North et al. 2009). Claudio Bordignon presented clin-
ical results of studies attempting to solve the problem of graft-
versus-host disease, which is an important problem after bone
marrow transplantation. Bordignon described a gene therapy
that selectively removes cytotoxic T cells and reduces the inci-
dence of graft-versus-host disease in several different clinical
settings (Ciceri et al. 2009). The speed of progress is encour-
aging and shows the benefit of manipulating a well-defined
cellular target.
The Niche
The germ cells have a case for being the once and future stem
cell. Genetic studies have defined the interacting cell typesCell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCR 485
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sperm from germ cells in Drosophila. In the Drosophila testis,
there are fewer spermatogenic stem cells as flies get older.
Leanne Jones (Salk Institute) reported that overexpression of
unpaired (the factor controlling spermatogenic stem cells that
is released from the hub cell niche in the testes) allows rejuvena-
tion of these old spermatogenic stem cells.
The specific sites supporting HSCs in development speaks
to the importance of local cell interactions, the niche. Hanna
Mikkola (UCLA) and Trista North (Harvard University) described
effects of blood flow on the maturation of blood stem cells
during mouse and zebrafish development, respectively. The
NCX1 gene is a voltage-dependent calcium channel that may
be the target for drugs that are widely used to treat heart
disease. Loss of NCX1 gene causes embryonic lethality at
embryonic day 9.0 in the mouse. In the mutant mouse, the
heart never functions, so HSCs remain at the site where they
are initially made—the origin niche. Mikkola reported that inde-
pendent sites generate blood, including the yolk sac, AGM
region, and the placenta (with the placenta having 153 more
blood stem cells than the other two sites; Rhodes et al.,
2008). This group is using their ability to isolate HSCs to estab-
lish an artificial niche and to ask if this niche will promote the
differentiation of HSCs from human ESCs. Although blood
stem cells are present in the AGM without blood flow, they
fail to suppress the endothelial markers that reflect their lineage
origin. In zebrafish, blood flow also regulates HSC develop-
ment. HSCs are generated at an endothelial surface where
gas exchange occurs, and North showed that administration
of exogenous nitric oxide could rescue the maturation of
blood stem cells in zebrafish without blood flow (North et al.,
2009).
In adult mammals, HSCs are usually found in the bone marrow
where they interact with bone cells and vascular elements.
ShaneMayack (Joslin Diabetes Center) found that the osteoblast
niche of blood stem cells in the bone marrow of old mice
changes the numbers and differentiation properties of these
blood stem cells (Mayack and Wagers, 2008). However, hetero-
chronic parabiosis of old and young mice led to rejuvenation of
blood cells in the older mouse. This result is similar to the rejuve-
nation of adult muscle stem cells, as discussed at themeeting by
Irina Conboy (UC Berkeley; Conboy et al., 2005).
TheWnt signaling pathway plays a central role in regulating the
differentiation of the skin, the largest and one of the most
dynamic organs in the body. Tcf3, a bHLH transcription factor,
acts downstream of the Wnt/b-catenin to regulate both uncom-
mitted and differentiating cells in the developing skin. Elaine
Fuchs (Rockefeller University, New York) showed that Tcf3 and
Tcf4 have Wnt-independent and different roles in the timing of
stem cell cycling in the adult skin (Nguyen et al., 2009). Although
traditionally the stem cells in the bulge region of the hair follicle
have been thought to initiate a new hair cycle, Valentina Greco
(Rockefeller University) demonstrated that the hair-growth cycle
is initiated by FGF7 that stimulates proliferation of cells in the hair
germ (between the bulge and the dermal papilla), which
contribute to the growing hair follicle before the contribution of
new cells from the bulge begins (Greco et al., 2009). In the blood,
the skin, and other tissues, the aging of the niche is coming into
sharper focus.486 Cell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCRTechnical Advances In Vitro and In Vivo
Technical development is a central part of our field. In some
cases, the motivation is clinical advance, and in others, curiosity
is the motivating force. One of the limiting factors for blood stem
cell transplantation is the inability to substantially expand blood
stem cells in culture. Peter Zandstra (University of Toronto)
argued that quantitative modeling of feedback signals in culture
from the progenitor and differentiated blood cell progeny of the
stem cells may provide a better way to expand blood stem cells
in vitro (Kirouac and Zandstra, 2008). He suggested that the
niche could be reconstructed in a bioreactor by manipulating
both positive and negative feedback signals to the self-renewing
umbilical cord blood stem cells. Eric Deneault (University of
Montreal) used a gene-engineering approach to look for factors
that would increase blood stem cell self-renewal. He foundmore
than a dozen new factors that increased blood stem cell self-
renewal, and themajority of thesewere validated in vivo in recon-
stitution assays after transplant of the manipulated blood stem
cells. Perhaps most surprising, two of the factors (Fos and
STP1) did not work directly but increased the recruitment of
host blood stem cells (Deneault et al., 2009). Thus, even in a
screen for intrinsic control of stem cells, the importance of cell
interaction was found.
At any time, the cells of the blood come from a restricted set of
the stem cells. Fernando Camargo (Harvard University) has
improved on the previous methods for marking distinct stem
cell lineages by using a drug inducible transposase to mark
blood stem cells without irradiation or transplantation. Camargo
used clonal tracking to show that only a small fraction of blood
stem cells actively make progeny at any one time. An elegant
technological advance gives insight into the control of precursor
cell proliferation in living humans. Jonas Frisen (Karolinska Insti-
tute, Stockholm) realized that the limited period in the 1950s and
1960s of above-ground nuclear testing would label humans with
carbon-14 and allow a human version of the label-retaining
experiment that has been used in many experimental models
to identify stem cells. They showed that the loss of the C14 label
in DNA in the dentate gyrus of the adult human hippocampus
from people who have died at various times since the nuclear
testing shows that these neurons are being replaced. Their
most recent results suggest a small but interesting turnover of
cardiomyocytes in the human heart (Bergmann et al., 2009).
Frisen speculated that this approach could be used to define
the effects of different environments and different genomes on
precursor cell turnover in human tissues. New technologies
continue to promise rapid advances in the brave new world of
stem cell biology.
Pluripotency and Self-Renewal
The current interest in human pluripotent stem cells rests on the
belief that they can be maintained in a stable state in cell culture
over many cell divisions. In a lecture, dedicated to the late Anne
McLaren, Janet Rossant (Hospital for Sick Children, Toronto)
presented data on the earliest cell-fate decisions in the mamma-
lian embryo—differentiation into trophoblast and primitive endo-
derm cells. Her results show that, in contrast tomouse ESCs that
appear to be largely independent of FGF signaling, trophoblast
stem cells and endoderm stem cells are particularly dependent
on this signaling pathway.
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and extra-embryonic cell types of the developing embryo can be
expanded as cell lines. The embryo is derived from pluripotent
cells and there are now four pluripotent cell types that have
been derived from the mouse: embryonic stem cells (ESCs),
embryonic germ (EG) cells, epiblast stem (EpiS) cells and
induced pluripotent stem cells (iPSCs). Like human ESCs, FGF
promotes the self-renewal of mouse EpiS cells. Mouse ESCs
and EpiS cells are also distinct in their responses to LIF. Another
important distinction is the inability of the EpiS cell to incorporate
into the inner cell mass after injection into the blastocyst. EpiS
cells were initially derived from mouse embryos after they
implant 5.5 days after fertilization. Azim Surani (Cambridge
University) reported that EpiS cells can be derived from the post-
implantation mouse embryo even 7.5 days after fertilization. He
also showed that these cells can spontaneously reprogram
into ESCs that can generate chimeric mice after blastocyst injec-
tion. This transition was achieved without exogenous genetic
manipulation when the cells were simply placed in conditions
that support ESCs (Bao et al., 2009). Another advance was sug-
gested by Catherine Browne (Griffith University, Brisbane), who
reported that pluripotent stem cells could be isolated from the
adult mouse olfactory mucosa without genetic manipulations.
This derivation of pluripotent stem cells from adult tissues has
implications for the mechanisms for pluripotency.
EG cells are derived from primordial germ cells (PGCs) that
give rise to the gametes. Recent work identifies Lin28 as a regu-
lator of PGC differentiation and as a reprogramming factor (West
et al., 2009). Lin28 through inhibition of the microRNA let-7
regulates PGC specification at an early stage readily accessed
in differentiating ESCs. Richard Gregory (Children’s Hospital
Boston) showed that Lin28 regulates its target miRNA let-7 by
promoting its degradation through the addition of a terminal
Uridine (uridylation; Hagan et al. 2009). In a reversal of the
historic truth, the access we have to the relevant cells in culture
may make germ cell differentiation a general model to under-
stand how microRNAs regulate cell-fate decisions.
In the testis of mammals, large numbers of sperm are gener-
ated through an intermediate spermatogonial stem cell. Fruit
flies and mammals share fundamental aspects of germ line
control. During spermatogenesis in Drosophila, the PIWI genes
were first identified as regulating germline stem cell self-renewal.
Haifan Lin (Yale University, New Haven) discussed new data on
how the PIWI proteins regulate polysome formation and, through
this post-transcriptional mechanism, control the self-renewing
cell divisions in the seminiferous tubule (Wang et al., 2009). In
sperm, DNA is condensed to an extent that transcription is
massively inhibited providing an unusual opportunity to define
post-transcriptional controls of self-renewal.
The use of stem cell-based systems to define new advances in
molecular biology was continued by Richard Young (MIT, Cam-
bridge). He proposed an alternative view of transcriptional initia-
tion in ESCs that involves an initial short antisense transcript,
a role for MYC in regulating a step that permits transcriptional
elongation of the coding RNA, and assigns new roles for chro-
matin components in transcriptional control (Seila et al., 2008).
This rapid increase in our detailed knowledge of chromatin struc-
ture currently suggests iPS and ESCs are virtually identical in
terms of their epigenetic status.A dramatic illustration of epigenetic plasticity is the generation
of iPSCs from terminally differentiated cell types through reprog-
ramming. Konrad Hochedlinger (Harvard University) and Shinya
Yamanaka (Kyoto University) both focused on the major road-
block in reprogramming—the generally low efficiency of the
process (0.1%–1%). Hochedlinger proposed four possible
reasons: (1) stem/progenitor cells in starting tissues are easier
to be reprogrammed, yet they exist in low abundance; (2) low
efficiency of viral infection; (3) genetic alteration due to viral inser-
tion; and (4) reprogramming is a stochastic process. Using the
hematopoietic lineage as a testing ground, the Hochedlinger
lab has defined the efficiency of reprogramming at different
stages of the lineage. Hematopoietic stem cells are reprog-
rammed at 15.8% efficiency. Pro B cells can be reprogrammed
at 11.6% efficiency yet mature B cells can only be reprog-
rammed at 0.04% efficiency, 300-fold lower than their progen-
itors. Likewise, myeloid precursors can be reprogrammed at
27% efficiency, yet granulocytes can only be reprogrammed at
0.1% efficiency (Eminli et al., 2009). These observations suggest
that most differentiated cells have limited replicative potential,
thus, low reprogramming efficiency.
Shinya Yamanaka, Konrad Hochedlinger, and Hongkui Deng
(Beijing University) discussed data showing that p53 and associ-
ated components of stress response signaling p21, UTF1, and
Ink4a/Arf limit the efficiency of generating iPSCs (Hong et al.,
2009; Zhao et al., 2008). Yamanaka then further compared
iPSCs derived from embryonic fibroblasts, adult tail tip fibro-
blasts, adult hepatocytes, and gastric epithelial cells for their
differentiation potential by teratoma formation, chimerism, and
germline competency. In addition, the ability of iPSCs to differen-
tiate into neural cells was assessed by generating so-called
secondary neurospheres that were subsequently transplanted
into the striata of mice (SNS assay). Whereas iPSCs from
different origins gave rise to similar results on regular teratoma
studies, they show very different behavior in chimera and SNS
assays. Although mouse embryonic fibroblasts and gastric
epithelial cells give rise to iPSCs that are similar to embryonic
stem cells in their teratoma-forming propensity in the SNS assay,
iPSCs derived from hepatocytes show intermediate propensity
and iPSCs from the adult tail fibroblasts show the highest
propensity to form teratomas in the SNS assay (Miura et al.,
2009). These results suggest that iPSCs derived from different
donor cells vary substantially in their differentiation and tumor-
forming properties.
Cancer
Of course, mouse ESCs teach us that a teratoma is not neces-
sarily a ‘‘full-blown’’ tumor. There are many forms of develop-
mental variation, and theywill all be relevant to a field that aspires
to control development. The shortening of telomeres is a clear
genetic change, and Maria Blasco (CNIO, Madrid) extended
her previous work showing that telomere shortening is epigenet-
ically regulated in epidermal stem cells. She demonstrated that
telomere loss activates p53 and impaired mobility (Flores and
Blasco, 2009). She then demonstrated that during fibroblast
reprogramming into iPSCs, telomeres do not reach expected
length immediately but achieve this after multiple passages
(Marion et al., 2009). Blasco concluded that iPSCs could only
be generated when adult cells have long telomeres, whereasCell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCR 487
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death.
Barriers in epigenetic reprogramming were also discussed by
Juan Carlos Izpisu`a Belmonte (Center of Regenerative Medicine,
Barcelona). He showed that p53-deficient cells are amenable to
reprogramming and that cells deficient for FANC, a DNA repair
gene, can only be reprogrammed at low frequencies seem to
support this hypothesis. Strikingly, genetically ‘‘repaired’’ FANC
(after reintroduction of the gene) regained not only full reprogram-
ming potential but also the ability to differentiate into hematopoi-
etic cells, suggesting that gene therapy and iPS technology may
provide a novel therapeutic strategy (Raya et al., 2009).
Promyelocytic leukemia (PML) is caused by fusion of the PML
nuclear protein with RARa that regulates the function of the
tumor suppressor PTEN. Luciano Di Croce (Center for Genomic
Regulation, Barcelona) has determined how this modified tran-
scription factor is capable of interacting with key components
of the epigenetic machinery including PRC2, but may also
have identified a specific temporal mode of action where both
the histone demethylase UTX and Zrf1 connect DNAmethylation
and histone modification with transcriptional silencing (Morey
et al., 2008). Eduard Batlle (IRB, Barcelona) explored the intes-
tinal stem cell (ISC) origin of colorectal cancer (CRCs) and the
role of Eph-ephrin andWnt signaling pathways in its progression.
Batlle reviewed that the majority of human colorectal cancers
(CRCs) are initiated by mutations in the tumor suppressor gene
Apc, which switches on the Wnt pathway in a constitutive
fashion. He then reported that beta-catenin and most Wnt target
genes induced by APC mutations in CRCs, such as the EphB1,
-2, and -3 receptors of ephrinB ligands, are expressed at the
highest levels in ISCs in normal intestine and then progressively
decrease in transient amplifying progenitors and more differenti-
ated intestinal epithelial cells. Using EphB2 as a marker allows
the isolation of ISCs and more differentiated intestinal cells.
Remarkably, during initial CRC progression, beta-catenin and
EphB receptors expend their expression along the crypt epithe-
lium (Cortina et al., 2007). However, EphB2 and EphB3 suppress
CRC progression beyond the early stages of tumor develop-
ment. Most colorectal cancers silence the expression of EphB
receptors around the adenoma-carcinoma transition, despite
constitutive Wnt signaling. These observations illustrate how
the link between ISCs and CRCs may require an understanding
of the different roles EphB receptors play during early and malig-
nant stages of colorectal cancer progression.
This themeofconnecting stemcells tocancerwascontinuedby
Thea Tlsty (UCSF) and Jane Visvader (Walter & Eliza Hall Institute,
Melbourne), both focusing on the mammary tissue. Building on
their previous isolation of mouse mammary gland stem cells that
are similar to basal subtype, Jane Visvader showed that GATA3
promotes the transition a more committed progenitor cell and
that Notch promotes further differentiation to the luminal lineage.
To extend these conclusions to humans, the Visvader group has
also isolated human basal stem/progenitor cells, luminal progen-
itors, and mature luminal cells; determined their molecular signa-
tures; and examined how these molecular signatures change
during the BRCA-induced early cancer groups (Lim et al., 2009).
Thea Tlsty explored how mammary epithelial stem cells
acquire epigenetic plasticity that predisposes them to become
tumors. She reported that mammary epithelial cells from women488 Cell Stem Cell 5, 483–489, November 6, 2009 ª2009 ISSCRfree of cancer, when examined in vitro, contain a subpopulation
of variant mammary epithelial cells that can continuously grow,
bypassing stress-response mediated arrest. This growth is
caused by methylation of the promoter of p16INK4a leading, in
turn, to epigenetic and genetic mosaicism, including telomere
instability (Dumont et al. 2008). Importantly, this clonal expansion
phase of tumorigenesis is supported by TGFb signals from
stromal cells that promote the epithelial-to-mesenchymal transi-
tion andmalignancy. Key features of tissue and cancer stemcells
seem to be regulated by similar molecular and cellular rules.
Are There General Rules?
But is cell identity and number controlled by stable evolutionary
rules? Jeremy Brockes (University College, London) described
the dependence of adult limb regeneration in salamander on
neural innervation. Nerves induce the expression of a factor
(AG2) in Schwann cells at the margin of a cut limb. AG2 is then
expressed in glandular cells that are critical for regeneration of
the limb skeleton. Interestingly, the neural innervation itself
induces the dependence of limb regeneration on neural innerva-
tion. Preventing nerve growth into the limb during early develop-
ment allows limb regeneration in the adult without AG2 and
without neural innervation (Kumar et al., 2007). The regenerating
newt limb gave us another surprise. Elly Tanaka (Center for
Regenerative Therapies Dresden) described the regeneration
of the limb in the developing newt. Using transgenic newts where
fluorescent transgenes marked different cell lineages, she
showed that the cells in the blastema that regenerate the limb
are not multipotent stem cells but, rather, committed progenitors
for muscle, skin, and Schwann cells (Kragl et al., 2009). In the
newt, limbs are imprinted by nerves, and committed cells can
be activated. Another surprise came from Yann Barrandon
(EPF, Laussane), who suggested transdifferentiation from one
epithelial population to another was possible.
What will it take to define general rules of development?
Olivier Pourquie (Stowers Institute for Medical Research, Kansas
City) showed that mouse mesodermal tail bud stem cells are
segmented into somites at a specific determination point as
they migrate rostrally through the action of a clock that oscillates
every 2 hours and controls segmentation through the sequential
activation of Notch/FGF versus Wnt. Pourquie suggested that
defining the state of thousands of molecules through time was
the way to understand somite formation (Aulehla and Pourquie´,
2008). Pourquie encouraged us to define the general rules of
development by constructing databases containing the molec-
ular changes that define cell lineages in different species. The
energy and insight of the science presented in Barcelona
suggests that he will have enthusiastic support from around
the world. For an update on all these exciting ideas, come to
San Francisco in 2010.
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